| Document |
Document Title |
|
WO/2006/058648A2 |
The present invention relates to compounds of Formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and...
|
|
WO/2006/054652A1 |
An FAAH inhibitor; and a preventive/therapeutic agent for cerebrovascular disorders and a preventive/therapeutic agent for sleep disorders which each contains the inhibitor. The FAAH inhibitor is a compound represented by the formula (I0...
|
|
WO/2006/055184A2 |
The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
|
|
WO/2006/054102A1 |
The present invention pertains to synthetic analogues of microcin B17 component units, methods of making and using these analogues, including, for example, as inhibitors of DNA gyrase. More particularly, the present invention pertains to...
|
|
WO/2006/051704A1 |
An imine compound represented by the formula (X) (wherein A represents a heterocyclic group; R1, R2, and R3 each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkox...
|
|
WO/2006/049215A1 |
It is intended to provide a combination drug for preventing and/or treating an autoimmune disease. More specifically speaking, a combination drug for preventing and/or treating an autoimmune disease which contains a CaMKII inhibitor and ...
|
|
WO/2006/045554A1 |
The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment o...
|
|
WO/2006/046914A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded an...
|
|
WO/2006/044412A1 |
The invention encompasses novel compounds of a formula I and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.
|
|
WO/2006/042478A1 |
The present invention is directed to a series of small-molecule inhibitors of general formula (I), which are designed on the crystal structure of SARS coronaviral main protease. Preparation of the said small-molecule inhibitors, pharmace...
|
|
WO/2006/044359A2 |
Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, Rla, R6, Xa, Xb and Y are as descr...
|
|
WO/2006/044975A2 |
The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds m...
|
|
WO/2006/042245A1 |
The present invention relates to novel isoxazole compounds of formula (I) having (PPAR) agonist activity, pharmaceutical compositions containing such compounds and methods for their use.
|
|
WO/2006/040351A1 |
The present invention relates to compounds of formula (I): in which R1, R2, R3, X, Y and A are as defined in the specification. The compounds are modulators of the estrogen receptors.
|
|
WO/2006/037480A1 |
The invention is concerned with hexafluoroisopropanol substituted ether derivatives of formula (I), wherein Rl to R3 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. The...
|
|
WO/2006/037945A1 |
Compounds of formula: (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides. Also claimed are processes for the preparation of the claimed compounds, a herbicidal composition comprising the claimed co...
|
|
WO/2006/038657A1 |
Disclosed are 3-bromo-5,5-dimethyl-4,5-dihydroisoxazole and a simple and safe method for producing the same with high yield. Specifically disclosed is a method for producing 3-bromo-5,5-dimethyl-4,5-dihydroisoxazole represented by the fo...
|
|
WO/2006/037982A2 |
The invention relates to substituted acids as useful pharmaceutical compounds for treating respiratory disorders as asthma, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2006/034333A2 |
Trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasit...
|
|
WO/2006/033551A1 |
The present invention relates to a dicarbonylamino-isoxazoline derivative as an inhibitor against various caspases and a therapeutic composition for preventing inflammation and apoptosis comprising the same.
|
|
WO/2006/030211A2 |
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...
|
|
WO/2006/027684A1 |
This invention is directed to compounds of formula la, lb or Ic and to pharmaceutical compositions thereof: formula (Ia), formula (Ib), formula (Ic) or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are...
|
|
WO/2006/024820A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides. Also claimed is a process for the preparation of compounds of the formula I, wherein m is 2 and n is 1, and the other substi...
|
|
WO/2006/023844A2 |
Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and...
|
|
WO/2006/021806A1 |
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.
|
|
WO/2006/021759A1 |
The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, a...
|
|
WO/2006/021805A1 |
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO/2006/020951A1 |
The present invention relates to compounds which modulate the activity of the SI P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1 P1 receptor, and pharmaceutical compositions compri...
|
|
WO/2006/015852A1 |
Compounds of formula (I) in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergi...
|
|
WO/2006/011466A1 |
Disclosed are a compound and pharmaceutically acceptable salts thereof represented by the general formula (1) below. (In the formula (1), R1, R2, R3, R4 and X are the same as R1, R2, R3, R4 and X defined in the description.)
|
|
WO/2006/009869A1 |
One aspect of the present invention relates to isoxazoline derivatives that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising an isoxazoline derivative of the invent...
|
|
WO/2006/009134A1 |
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...
|
|
WO/2006/004030A1 |
A pharmaceutical having the potency of inhibiting the production of tissue factors, which pharmaceutical comprises an LXR ligand as an active ingredient. There is provided a pharmaceutical for the treatment and/or prevention of vascular ...
|
|
WO/2005/123667A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2005/123073A1 |
The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia caver...
|
|
WO/2005/123701A1 |
The disclosure provides a method for the preparation of a diarylisoxazolé sulfonamide compound comprising contacting a deoxybenzoin with a secondary amine to form a diarylenamine compound; contacting the diarylenamine compound with an a...
|
|
WO/2005/120515A2 |
Disclosed herein are carbonyl compounds of having the structural formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not l...
|
|
WO/2005/120499A1 |
The invention provides for obtaining Form A of valdecoxib with desirable particle size characteristics without milling, making it useful as an active ingredient in the preparation of pharmaceutical composition.
|
|
WO/2005/118532A1 |
A process for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselect...
|
|
WO/2005/119315A2 |
In one aspect, the present invention provides a hyperpolarizable organic chromophore. The chromophore is a nonlinear optically active compound that includes a &pgr -donor conjugated to a &pgr -acceptor through a &pgr -electron conjugated...
|
|
WO/2005/113519A1 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...
|
|
WO/2005/112945A2 |
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among man...
|
|
WO/2005/110971A1 |
The invention relates to substituted cyclohexyl-1,4-diamine derivatives, a method for the production thereof, medicaments containing these compounds, and to the use of substituted cyclohexyl-1,4-diamine derivatives for producing medicame...
|
|
WO/2005/108347A2 |
The invention relates to substituted enaminones of Formula (I) and their derivatives and the discovery that these compounds modulate the effect of &gammad -aminobutyric acid (GABA) on the GABAA receptor complex in a therapeutically relev...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/105733A1 |
The invention provides a compound of the formula (I): wherein X represents a carbon atom or the like : Y represents imino, or the like: Z represents a hydrogen atom or the like: R1 represents an alkyl group having from 1 to 6 carbon atom...
|
|
WO/2005/105770A2 |
The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The prese...
|
|
WO/2005/105744A1 |
This invention is directed to a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or conditi...
|
|
WO/2005/105764A1 |
Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the...
|
|
WO/2005/102980A1 |
The invention relates to compounds of formula (1), wherein Z is a hydrogen or halogen atom; R'F is a perfluoroalkyl group CnF2n+1 in which n is an integer ranging from 1 to 12; R is in an ortho, meta or para position and represents an el...
|
